厄贝沙坦对老年非ST段抬高型心肌梗死患者血清肝细胞生长因子水平的影响.docVIP

厄贝沙坦对老年非ST段抬高型心肌梗死患者血清肝细胞生长因子水平的影响 　　[摘要] 目的 观察厄贝沙坦对老年非ST段抬高型心肌梗死（NSTEMI）者血清肝细胞生长因子（HGF）水平的影响。 方法 选择2013年10月～2014年5月哈尔滨医科大学附属第四医院老年NESTMI患者38例，将入选患者中因各种原因不能服用厄贝沙坦的17例患者作为对照组，余21例为药物组。对照组给予硝酸酯药物、β受体阻滞剂、阿托伐他汀、拜阿司匹林、低分子肝素等常规治疗；药物组在此基础上给予常规治疗联合厄贝沙坦（150 mg/d）。分别于治疗前、治疗后第7天、治疗后第14天检测两组患者血清超敏C反应蛋白（hs-CRP）、同型半胱氨酸（Hcy）；采用酶联免疫吸附试验检测血清中HGF含量。 结果 治疗后第14天时药物组血清hs-CRP及Hcy水平均较治疗前明显降低（P 0.05）。 结论 老年非NSTEMI患者应用厄贝沙坦2周时可使血清中hs-CRP、Hcy水平明显下降，厄贝沙坦可降低老年NSTEMI患者血清HGF水平。 　　[关键词] 厄贝沙坦；老年；非ST段抬高型心肌梗死；肝细胞生长因子 　　[中图分类号] R542.23 [文献标识码] A [文章编号] 1673-7210（2015）08（a）-0140-04 　　Effect of Irbesartan on HGF in elderly patients with non-ST-elevation myocardial infarction 　　HU Shuang YU Junmin ZHANG Xiaobo LI Dahe WANG Huidong 　　The First Department of Geriatrics， the Fourth Afiliated Hospital of Harbin Medical University， Heilongjiang Province， Harbin 150001， China 　　[Abstract] Objective To investigate the effects of Irbesartan on hepatocyte growth factor （HGF） in elderly patients with non-ST-elevation myocardial infarction （NSTEMI）. Methods 38 elderly patients with NSTEMI from October 2013 to May 2014 in the Fourth Afiliated Hospital of Harbin Medical Universit were selected， and 17 cases who couldn’t take Irbesartan were as control group， the others were as the drug group. The control group was given conventional therapy， such as nitric acid ester， β-receptor blocker， atorvastain， bayaspirin， low molecular heparin， and the drug group was given conventional therapy combined with Irbesartan （150 mg/d）. The levels of serum hs-CRP， Hcy of two groups were measured before and 7， 14 days after treatment respectively， and the levels of HGF were detected by ELISA，. Results After treatment 14 days， the levels of hs-CRP and Hcy were significant decreased than those before treatment and the control group （P 0.05）. Conclusion After 2 weeks treatment with Irbesartan， the levels of serum hs-CRP and Hcy in elderly patients with NSTEMI can be reduced significantly， Irbesartan can reduce the level of s